Paradigm Biopharmaceuticals Limited (ASX:PAR) Insider Acquires A$20,108.30 in Stock

Paradigm Biopharmaceuticals Limited (ASX:PAR) insider Paul Rennie bought 95,300 shares of Paradigm Biopharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average price of A$0.21 ($0.14) per share, with a total value of A$20,108.30 ($13,405.53).

Paradigm Biopharmaceuticals Price Performance

The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.93 and a current ratio of 7.22.

Paradigm Biopharmaceuticals Company Profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.